Fundz

Cingulate

Kansas City, Kansas, United States · Biopharma, Biotechnology, Healthcare

Cingulate® is a biopharmaceutical company utilizing its innovative Precision Timed Release™ (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. We aim to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an

You have opened 5 full company profiles today. Create an account to keep reading them. Create an account

Key facts

Headquarters
Kansas City, Kansas, United States
Employees
22
Industries
Biopharma, Biotechnology, Healthcare
Status
Public (CING)
Website
www.cingulate.com
LinkedIn
Company page

Recent activity at Cingulate

  • : SEC 8-K (1.01): On November 13, 2026, Cingulate Inc. entered into Amendment No. 2 to its existing ATM Sales Agreement with A.G.P./Alliance Global Partners and added Maxim Group LLC as an additional sales agent. This amendment allows the Company to continue its strategy of offering and selling common stock valued at up to $100,000,000 through the agents. The addition of Maxim Group LLC is expected to enhance market reach and execution capabilities for the Company’s capital raising efforts. The original agreement was disclosed on March 24, 2026, indicating a long-term strategy for capital management.
  • : SEC 8-K (8.01):
  • : SEC 8-K (5.02): On September 30, 2026, Cingulate Therapeutics LLC, a wholly owned subsidiary of Cingulate Inc., entered into amendment No. 2 to the Employment Agreement with Matthew N. Brams, who serves as the Executive Vice President and Chief Medical Officer. This amendment is effective as of January 1, 2026, and may include adjustments to his compensatory arrangements. The strategic implications might involve changes in leadership dynamics or shifts in the direction of medical strategy within the company, although specific financial details related to the amendments have not been disclosed. As this event occurred within the past 3 days, it is categorized under Item 5.02 concerning changes in officers.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

About Cingulate: questions and answers

What does Cingulate do?

Cingulate® is a biopharmaceutical company utilizing its innovative Precision Timed Release™ (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. We aim to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an

Where is Cingulate headquartered?

Cingulate is headquartered in Kansas City, Kansas, United States.

How many employees does Cingulate have?

Cingulate has about 22 employees.

What is the latest news on Cingulate?

On Sep 30, 2026, SEC 8-K (1.01): On November 13, 2026, Cingulate Inc. entered into Amendment No. 2 to its existing ATM Sales Agreement with A.G.P./Alliance Global Partners and added Maxim Group LLC as an additional sales agent. This amendment allows the Company to continue its strategy of offering and selling common

Is Cingulate a public company?

Yes. Cingulate is publicly traded under the ticker CING.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Cingulate across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.